Asymmetric Capital Partners

Asymmetric Capital Partners is a pre-seed and seed firm that founder Rob Biederman built off the back of his own operating exit at Catalant Technologies, and the firm’s posture reflects that lineage. Boston-based, with around $240M in AUM after a $137M Fund II close in 2025, Asymmetric writes concentrated checks into B2B SaaS, marketplaces, fintech, and digital health, with a strong preference for capital-efficient, founder-led companies. The firm’s disclosed healthcare-relevant positions are limited but illustrative. EvolutionIQ, an AI-driven claims guidance platform serving disability and workers’ compensation insurers, sits squarely at the intersection of insurance technology and healthcare-adjacent software. Torc and Zorus represent the firm’s broader B2B technology bets. Asymmetric is not a healthcare specialist, and founders should read it instead as a generalist B2B firm that is willing to underwrite digital health when the company resembles a software business more than a clinical services business.

The stated thesis is to back pre-seed and seed B2B companies in SaaS, marketplaces, digital health, and fintech, with concentrated ownership a stated priority. The team self-describes as former founders and operators. The implied target company is a two to four person team, often pre-revenue or in early commercial pilots, building a B2B software product with a clear distribution path to mid-market or enterprise customers. In digital health, that translates to provider workflow tools, payer-facing software, employer benefits platforms, and the kind of healthcare admin or operations tooling that looks more like vertical SaaS than like a regulated medical product. Founders building therapeutics, devices, or clinical services companies are not the target.

The disclosed portfolio leans toward classic B2B vertical SaaS. EvolutionIQ is the clearest healthcare-adjacent position, with a product that uses machine learning to surface high-priority claims for case managers in long-term disability and workers’ compensation, an area that touches healthcare cost containment without being a regulated medical device. Torc and Zorus represent broader B2B exposure. The relatively small number of disclosed positions reflects the firm’s concentration model: rather than spraying small checks across many companies, Asymmetric writes meaningful pre-seed and seed checks and reserves heavily for follow-on. Founders should expect the firm to disclose only a portion of its actual portfolio publicly and should ask for additional references during diligence.

Check size is listed at $1M to $5M, with Asymmetric leading or co-leading at pre-seed and seed. With Fund II at $137M, the firm has the reserve capacity to follow into Series A and Series B with select winners. Co-investors at the seed level tend to include other B2B-focused seed firms and operator angels rather than healthcare specialists, which has implications for downstream syndication: a digital health founder backed by Asymmetric will likely need to bring in a healthcare specialist at the next round. The firm leans into ownership, so founders should expect a discussion about target ownership percentage and reserves rather than a small ride-along check.

The partnership is small and operator-heavy. Managing Partner Rob Biederman previously co-founded Catalant Technologies. Partners Nancy Chou and Sam Clayman handle additional investing leadership. Michele Spitzer leads portfolio and platform support, and Sarah Unger Biggs serves as COO. The team’s operator background means diligence focuses on go-to-market mechanics, founder defensibility, and capital efficiency rather than on therapeutic area expertise or clinical credentials. A founder pitching Asymmetric for a digital health company should be prepared to discuss B2B sales cycles, ACV, payback periods, and net retention.

Warm intros from operator-founder networks in Boston and New York carry weight, as do referrals from other B2B seed funds. Biederman maintains a public profile through writing on company building and through occasional podcast appearances oriented to early-stage B2B SaaS rather than healthcare specifically. Founders should approach with a B2B narrative first and a healthcare narrative second. Cold inbound through the firm’s website is plausible if the deck demonstrates B2B fundamentals; founders without strong introductions should not over-invest in clinical or regulatory framing in their first contact.

Approach Asymmetric when your digital health company is structurally a B2B software business with credible mid-market or enterprise distribution. Do not approach for therapeutics, devices, clinical services, or consumer health products, none of which fit. Among portfolio founders, the firm has a reputation for concentrated, hands-on early support and for being willing to lead pre-seed when most institutional firms wait until product is more mature. Founders who want a healthcare specialist board partner with clinical relationships will find Asymmetric a poor fit; founders who want a sharp B2B operator-investor at company formation will find the firm one of the better options in its weight class.